What Edwards Lifesciences's latest 10-Q says: 5 signals
Edwards Lifesciences filed its latest 10-Q with the SEC on Aug 4, 2026. It discusses acquisition completed, capex increase and CFO change.
Public (EW)Medical Equipment Manufacturing10,000+ employeesedwards.comLinkedIn
- Filed
- Aug 4, 2026
- Filings
- 2
- Signals
- 13
10-Q · latest 10
What Edwards Lifesciences's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 5 signals
Edwards Lifesciences appoints Theodora Mistras as new CFO, effective May 2026.
Completed acquisition of Autus for $128.9M, signaling system integration needs.
The completion of the Autus acquisition for $128.9M in February 2026 will necessitate the integration of disparate business processes, data, and IT systems.
$128.9M
Total consideration for Autus acquisition
The IRS is proposing massive adjustments to taxable income ($625.3M for 2018, $530.7M for 2019, and $683.6M for 2020) related to transfer pricing.
$1.8B
Total proposed increase to U.S. taxable income for 2018-2020 from new IRS Notices of Proposed Adjustment (NOPAs).
Contesting $269.3M IRS tax deficiency notice in court for 2015-2017 tax years.
The company is escalating a major tax dispute with the IRS to the judicial process, creating significant legal costs, financial uncertainty, and a need for specialized tax and legal advisory services.
$269.3M
Additional tax sought by IRS for 2015-2017 tax years being contested in court.
Capital expenditures increased 25% YoY to $131.8M in the first half of 2026.
The company increased its investment in capital projects by over $26M compared to the same period last year, indicating available budget and active spending on infrastructure, facilities, or equipment.
$131.8M
Capital expenditures for the six months ended June 30, 2026.
25%
Year-over-year increase in capital expenditures for the six-month period.
Becton, Dickinson and Company
- SEC EDGAR
10-Q
Filed · 8 signals
Contesting $269.3M IRS tax deficiency for 2015-2017 via judicial process
After failing to resolve a transfer pricing dispute with the IRS Independent Office of Appeals, the company is now pursuing litigation to contest a $269.3 million tax deficiency.
$269.3M
Additional tax sought by IRS for 2015-2017 tax years
Edwards Lifesciences completes acquisition of Autus Valve Technologies for $128.9M
Completed in February 2026 with $35.1M in cash, this acquisition expands their portfolio and signals a strategic focus on inorganic growth in valve technologies.
$128.9M
Total consideration for acquisition of Autus Valve Technologies
Operating cash flow plummeted by $236.6M in Q1 2026 due to working capital needs
Net cash from operations fell sharply to $43.8 million from over $280 million in the prior year, a decrease of $236.6 million.
$236.6M
Year-over-year decrease in net cash from operating activities for Q1
Spent $520.1M on share repurchases in Q1 2026 with $1.5B remaining authorization
The company executed a $500 million accelerated share repurchase and spent a total of $520.1 million on buybacks in the first quarter.
$1.5B
Remaining authority for share repurchase program
Edwards Lifesciences finalizes divestiture of Critical Care unit to Becton Dickinson
The company is making post-sale working capital adjustments ($36.3M in the prior year) related to the sale, indicating the complexities of separating the business.
$36.3M
Net working capital adjustment related to the sale of Critical Care in the prior year period
Becton, Dickinson and Company
Showing 10 of 13 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Edwards Lifesciences earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| CFO transitioning out by mid-2026, successor search underwayThe long-tenured CFO is transitioning out, and a search for a successor has been initiated. A new CFO will likely review all financial systems, processes, and vendor relationships, creating significant opportunities for new financial software and services providers. | |
| Partnering with AI and tech companies for workflow and screening solutions.The company is actively partnering with AI-based tech companies to improve efficiencies in patient screening and create workflow solutions. This is a direct signal of investment in AI and data analytics, creating opportunities for technology vendors. | |
| Actively partnering with AI and tech companies for workflow solutionsThe company is explicitly using partnerships with AI and technology firms to improve patient identification and create economic workflow solutions. This signals an active budget and receptiveness to vendors offering AI-powered screening, data analytics, and process automation tools. | |
| Increasing R&D spending to strategically prioritize structural heart portfolio.R&D spending increased to $281 million in Q3, reflecting an intentional strategy to invest heavily in the expanding structural heart portfolio. This signals where budget is being allocated and highlights a key area of focus for the company's growth. | |
| Expanding into new heart failure and aortic regurgitation marketsThe company is leveraging its expertise to extend into the new therapeutic areas of heart failure and aortic regurgitation. This major growth initiative will require significant, multi-year investment in R&D, clinical trials, and commercialization, opening doors for a wide range of suppliers and partners. | |
| Actively expanding new therapies across European countries.Following market approval for its KONECT therapy, the company successfully expanded its availability across multiple European countries in Q3. This demonstrates an active strategy of geographic expansion and product rollout, requiring investment in sales, marketing, and logistics. |
Signal API · MCP
Track Edwards Lifesciences with the Signal API
One POST /v1/companies/enrich call with edwards.com returns Edwards Lifesciences 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"edwards.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Edwards Lifesciences 10-Q
When did Edwards Lifesciences file its latest 10-Q?
What did Edwards Lifesciences disclose in its latest 10-Q?
What did Edwards Lifesciences say on its recent earnings calls?
Where can I read Edwards Lifesciences's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .